{"nctId":"NCT02410772","briefTitle":"TBTC Study 31: Rifapentine-containing Tuberculosis Treatment Shortening Regimens","startDateStruct":{"date":"2016-01-25","type":"ACTUAL"},"conditions":["Tuberculosis"],"count":2516,"armGroups":[{"label":"Regimen 1","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: control"]},{"label":"Regimen 2","type":"EXPERIMENTAL","interventionNames":["Drug: rifapentine"]},{"label":"Regimen 3","type":"EXPERIMENTAL","interventionNames":["Drug: rifapentine and moxifloxacin"]}],"interventions":[{"name":"rifapentine","otherNames":["Priftin"]},{"name":"rifapentine and moxifloxacin","otherNames":["Priftin and Avelox"]},{"name":"control","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Suspected pulmonary tuberculosis plus one or both of the following: a) at least one sputum specimen positive for acid-fast bacilli on smear microscopy OR b) at least one sputum specimen positive for M. tuberculosis by Xpert MTB/RIF testing, with semiquantitative result of 'medium' or 'high' and rifamycin resistance not detected.\n* Age twelve (12) years or older\n* A verifiable address or residence location that is readily accessible for visiting, and willingness to inform the study team of any change of address during the treatment and follow-up period.\n* Women of child-bearing potential who are not surgically sterilized must agree to practice a barrier method of contraception or abstain from heterosexual intercourse during study drug treatment.\n* Documentation of HIV infection status.\n* For HIV-positive individuals, CD4 T cell count greater than or equal to 100 cells/mm3 based on testing performed at or within 30 days prior to screening.\n* Laboratory parameters done at or within 14 days prior to screening:\n\n  * Serum or plasma alanine aminotransferase (ALT) less than or equal to 3 times the upper limit of normal\n  * Serum or plasma total bilirubin less than or equal to 2.5 times the upper limit of normal\n  * Serum or plasma creatinine level less than or equal to 2 times the upper limit of normal\n  * Serum or plasma potassium level greater than or equal to 3.5 meq/L\n  * Hemoglobin level of 7.0 g/dL or greater\n  * Platelet count of 100,000/mm3 or greater\n* For women of childbearing potential, a negative pregnancy test at or within seven (7) days prior to screening\n* Karnofsky score greater than or equal to 60\n* Written informed consent\n\nExclusion Criteria:\n\n* Pregnant or breast-feeding.\n* Unable to take oral medications.\n* Previously enrolled in this study.\n* Received any investigational drug in the past 3 months.\n* More than five (5) days of treatment directed against active tuberculosis within 6 months preceding initiation of study drugs.\n* More than five (5) days of systemic treatment with any one or more of the following drugs within 30 days preceding initiation of study drugs: isoniazid, rifampin, rifabutin, rifapentine, ethambutol, pyrazinamide, kanamycin, amikacin, streptomycin, capreomycin, moxifloxacin, levofloxacin, gatifloxacin, ofloxacin, ciprofloxacin, other fluoroquinolones, ethionamide, prothionamide, cycloserine, terizidone, para-aminosalicylic acid, linezolid, clofazimine, delamanid or bedaquiline.\n* Known history of prolonged QT syndrome.\n* Suspected or documented tuberculosis involving the central nervous system and/or bones and/or joints, and/or miliary tuberculosis and/or pericardial tuberculosis.\n* Current or planned use within six months following enrollment of one or more of the following medications: HIV protease inhibitors, HIV integrase inhibitors, HIV entry and fusion inhibitors, HIV non-nucleoside reverse transcriptase inhibitors other than efavirenz, quinidine, procainamide, amiodarone, sotalol, disopyramide, ziprasidone, or terfenadine. Individuals who are currently taking efavirenz-based antiretroviral treatment or for whom initiation of efavirenz-based antiretroviral treatment is planned within 17 weeks following enrollment may participate.\n* Weight less than 40.0 kg.\n* Known allergy or intolerance to any of the study medications.\n* Individuals will be excluded from enrollment if, at the time of enrollment, their M. tuberculosis isolate is already known to be resistant to any one or more of the following: rifampin, isoniazid, pyrazinamide, ethambutol, or fluoroquinolones.\n* Other medical conditions, that, in the investigator's judgment, make study participation not in the individual's best interest.\n* Current or planned incarceration or other involuntary detention.","healthyVolunteers":false,"sex":"ALL","minimumAge":"12 Years","stdAges":["CHILD","ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"TB Disease-free Survival at 12M After Study Treatment Assignment Among Participants in Control Regimen, Regimen1 (2HRZE/4HR) to Experimental Regimens, Regimen3 (2HPZM/2HPM) and Regimen2 (2HPZ/2HP) (Modified Intent to Treat [MITT] Population)","description":"To evaluate the efficacy of a rifapentine-containing regimen to determine whether the single substitution of rifapentine for rifampin makes it possible to reduce to seventeen weeks the duration of treatment for drug-susceptible pulmonary tuberculosis To evaluate the efficacy of a rifapentine-containing regimen that in addition substitutes moxifloxacin for ethambutol and continues moxifloxacin during the continuation phase, to determine whether it is possible to reduce to seventeen weeks the duration of treatment for drug-susceptible pulmonary tuberculosis A primary outcome status of \"favorable\", \"unfavorable\", or \"not assessable\" was assigned. For detailed definitions of outcomes please refer to: Dorman SE, at al. N Engl J Med. 2021 May 6;384(18):1705-1718.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"656","spread":null},{"groupId":"OG001","value":"645","spread":null},{"groupId":"OG002","value":"668","spread":null}]},{"measurements":[{"groupId":"OG000","value":"112","spread":null},{"groupId":"OG001","value":"139","spread":null},{"groupId":"OG002","value":"123","spread":null}]}]}]},{"type":"PRIMARY","title":"TB Disease-free Survival at 12M After Study Treatment Assignment Among Participants in Control Regimen, Regimen1 (2HRZE/4HR) to Experimental Regimens, Regimen3 (2HPZM/2HPM) and Regimen2 (2HPZ/2HP) (Assessable Population)","description":"* To evaluate the efficacy of a rifapentine-containing regimen to determine whether the single substitution of rifapentine for rifampin makes it possible to reduce to seventeen weeks the duration of treatment for drug-susceptible pulmonary tuberculosis\n* To evaluate the efficacy of a rifapentine-containing regimen that in addition substitutes moxifloxacin for ethambutol and continues moxifloxacin during the continuation phase, to determine whether it is possible to reduce to seventeen weeks the duration of treatment for drug-susceptible pulmonary tuberculosis A primary outcome status of \"favorable\", \"unfavorable\", or \"not assessable\" was assigned. For detailed definitions of outcomes please refer to: Dorman SE, at al. N Engl J Med. 2021 May 6;384(18):1705-1718.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"656","spread":null},{"groupId":"OG001","value":"645","spread":null},{"groupId":"OG002","value":"668","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"70","spread":null},{"groupId":"OG001","value":"107","spread":null},{"groupId":"OG002","value":"88","spread":null}]}]}]},{"type":"PRIMARY","title":"Percentage Participants With Grade 3 or Higher Adverse Events During Study Drug Treatment in Control Regimen (Regimen 1 2HRZE/4HR) Compared to Experimental Regimens, Regimen 3 (2HPZM/2HPM) and Regimen 2 (2HPZ/2HP) (Safety Analysis Population)","description":"* To evaluate the Safety of a rifapentine-containing regimen to determine whether the single substitution of rifapentine for rifampin makes it possible to reduce to seventeen weeks the duration of treatment for drug-susceptible pulmonary tuberculosis\n* To evaluate the Safety of a rifapentine-containing regimen that in addition substitutes moxifloxacin for ethambutol and continues moxifloxacin during the continuation phase, to determine whether it is possible to reduce to seventeen weeks the duration of treatment for drug-susceptible pulmonary tuberculosis Grade 3 or higher Adverse Events are collected by Clinical sites in systematic way through the laboratory tests and physical exam during regular study follow up visits and also in a non-systematic way when it was self-reported by participants during the study visits. The events are graded by site investigators per Common Terminology Criteria for Adverse Events (CTCAE V4.03","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"159","spread":null},{"groupId":"OG001","value":"119","spread":null},{"groupId":"OG002","value":"159","spread":null}]},{"measurements":[{"groupId":"OG000","value":"666","spread":null},{"groupId":"OG001","value":"716","spread":null},{"groupId":"OG002","value":"687","spread":null}]}]}]},{"type":"SECONDARY","title":"Proportion of Participants Who Are Culture Negative at Eight Weeks","description":"Proportion of participants who are culture negative at eight weeks, liquid media","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"523","spread":null},{"groupId":"OG001","value":"616","spread":null},{"groupId":"OG002","value":"641","spread":null}]}]}]},{"type":"SECONDARY","title":"Time to Stable Sputum Culture Conversion","description":"Time to stable sputum culture conversion, liquid media","paramType":"MEDIAN","dispersionType":"Inter-Quartile Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8.14","spread":null},{"groupId":"OG001","value":"8.14","spread":null},{"groupId":"OG002","value":"8.14","spread":null}]}]}]},{"type":"SECONDARY","title":"Discontinuation of Assigned Treatment for a Reason Other Than Microbiological Ineligibility (Tolerability)","description":"Tolerability of the regimen is evaluated using the outcome of discontinuation of assigned treatment for a reason other than microbiological ineligibility.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"61","spread":null},{"groupId":"OG001","value":"37","spread":null},{"groupId":"OG002","value":"55","spread":null}]}]}]},{"type":"SECONDARY","title":"Estimated Steady State Efavirenz PK Parameters Including Mid-dosing Interval Concentration","description":"Among participants with HIV infection receiving efavirenz-based antiretroviral therapy, number of participants who maintained plasma efavirenz concentrations ≥1 mg/L during TB treatment.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"62","spread":null}]}]}]},{"type":"SECONDARY","title":"TB Disease-free Survival at Eighteen Months After Study Treatment Assignment","description":"* To evaluate the efficacy of a rifapentine-containing regimen to determine whether the single substitution of rifapentine for rifampin makes it possible to reduce to seventeen weeks the duration of treatment for drug-susceptible pulmonary tuberculosis\n* To evaluate the efficacy of a rifapentine-containing regimen that in addition substitutes moxifloxacin for ethambutol and continues moxifloxacin during the continuation phase, to determine whether it is possible to reduce to seventeen weeks the duration of treatment for drug-susceptible pulmonary tuberculosis","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"656","spread":null},{"groupId":"OG001","value":"636","spread":null},{"groupId":"OG002","value":"667","spread":null}]},{"measurements":[{"groupId":"OG000","value":"112","spread":null},{"groupId":"OG001","value":"148","spread":null},{"groupId":"OG002","value":"124","spread":null}]}]}]},{"type":"SECONDARY","title":"TB Disease-free Survival at Eighteen Months After Study Treatment Assignment","description":"* To evaluate the efficacy of a rifapentine-containing regimen to determine whether the single substitution of rifapentine for rifampin makes it possible to reduce to seventeen weeks the duration of treatment for drug-susceptible pulmonary tuberculosis\n* To evaluate the efficacy of a rifapentine-containing regimen that in addition substitutes moxifloxacin for ethambutol and continues moxifloxacin during the continuation phase, to determine whether it is possible to reduce to seventeen weeks the duration of treatment for drug-susceptible pulmonary tuberculosis","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"656","spread":null},{"groupId":"OG001","value":"636","spread":null},{"groupId":"OG002","value":"667","spread":null}]},{"measurements":[{"groupId":"OG000","value":"69","spread":null},{"groupId":"OG001","value":"97","spread":null},{"groupId":"OG002","value":"79","spread":null}]}]}]},{"type":"SECONDARY","title":"Speed of Decline of Sputum Viable Bacilli by Automated Liquid MGIT Culture Days to Detection","description":"Parameter estimates of the nonlinear mixed effect models describing longitudinal time to positive (TTP)","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.14","spread":null},{"groupId":"OG001","value":"0.20","spread":null},{"groupId":"OG002","value":"0.24","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Sensitivity Analyses Assuming All Losses to Follow-up and Non-tuberculosis Deaths Have an Unfavorable Outcome","description":"A sensitivity analysis used to supplement the primary efficacy results and provide further insight into whether the intervention regimens should be considered to have non-inferior efficacy. This analysis considers the difference in proportion of unfavorable outcomes between the control arm and each of the experimental arms.\n\nMeasurement Description: The difference in proportion unfavorable was calculated using a stratified analysis using Cochran-Mantel-Haenszel weights. The analysis was stratified by HIV status and presence of cavitation only, and the stratified difference was considered primary.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"656","spread":null},{"groupId":"OG001","value":"645","spread":null},{"groupId":"OG002","value":"668","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Sensitivity Analyses Assuming All Losses to Follow-up and Non-tuberculosis Deaths Have a Favorable Outcome","description":"A sensitivity analysis used to supplement the primary efficacy results and provide further insight into whether the intervention regimens should be considered to have non-inferior efficacy.\n\nThis analysis considers the difference in proportion of unfavorable outcomes between the control arm and each of the experimental arms.\n\nMeasurement Description: The difference in proportion unfavorable was calculated using a stratified analysis using Cochran-Mantel-Haenszel weights. The analysis was stratified by HIV status and presence of cavitation only, and the stratified difference was considered primary.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"671","spread":null},{"groupId":"OG001","value":"650","spread":null},{"groupId":"OG002","value":"673","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":56,"n":825},"commonTop":["Neutropenia","Hepatitis"]}}}